Download Files:
PF-06952229
$350 – $3,000
Products Details
Product Description
– PF-06952229 is a potent, selective and orally active TGFbR1 inhibitor. PF-06952229 specifically binds to TGFbR1 and prevents TGFbR1-mediated signal transduction. PF-06952229 is a promising antineoplastic agent for the study solid tumors, especifically metastatic breast cancer[1].
Web ID
– HY-136244
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C23H24ClFN4O3
References
– [1]Flavia Mercer Pernasetti, et al. Combinations of tgfb inhibitors and cdk inhibitors for the treatment of breast cancer. Patent WO2020058820A1.
CAS Number
– 1801333-55-0
Molecular Weight
– 458.91
Compound Purity
– 99.92
SMILES
– O=C(NC(CO)CO)C1=CN=CC=C1NC2=CC(C3=CC(Cl)=CC=C3F)=NC=C2C(C)C
Clinical Information
– Phase 1
Research Area
– Cancer
Solubility
– DMSO : 50 mg/mL (ultrasonic)
Target
– TGF-β Receptor
Pathway
– TGF-beta/Smad
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
